JQJie-Ming Qu

Jie-Ming Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie-Ming Qu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nicotinic acetylcholine receptor variants associated with susceptibility to chronic obstructive pulmonary disease: a meta-analysis

    by Jing Zhang, Hanssa Summah, Ying-Gang Zhu, Jie-Ming Qu

    Background: Only 10-15% of smokers develop chronic obstructive pulmonary disease (COPD) which indicates genetic susceptibility to the disease. Recent studies suggested an association between COPD and polymorphisms in CHRNA coding subunits of nicotinic acetylcholine receptor. Herein, we performed a meta-analysis to clarify the impact of CHRNA variants on COPD. Methods: We searched Web of Knowledge and Medline from 1990 through June 2011 for COPD gene studies reporting variants on CHRNA. Pooled odds ratios (ORs) were calculated using the major allele or genotype as reference group. Results: Among seven reported variants in CHRNA, rs1051730 was finally analyzed with sufficient studies. Totally 3460 COPD and 11437 controls from 7 individual studies were pooled-analyzed. A-allele of rs1051730 was associated with an increased risk of COPD regardless of smoking exposure (pooled OR = 1.26, 95% CI 1.18-1.34, p < 10-5). At the genotypic level, the ORs gradually increased per A-allele (OR = 1.27 and 1.50 for GA and AA respectively, p < 10-5). Besides, AA genotype exhibited an association with reduced FEV1% predicted (mean difference 3.51%, 95%CI 0.87-6.16%, p = 0.009) and increased risk of emphysema (OR 1.93, 95%CI 1.29-2.90, p = 0.001). Conclusions: Our findings suggest that rs1051730 in CHRNA is a susceptibility variant for COPD, in terms of both airway obstruction and parenchyma destruction.


    • 1 October 2008
      • Vol. 31  (10) , 725-6

    [Clinical applications of macrolides for respiratory diseases in China].

    by Jie-Ming Qu, Jing Zhang

    • 1 July 2008
      • Vol. 31  (7) , 509-12

    [The role of gastro-intestinal tract microorganisms in the development of ventilator-associated pneumonia: an experimental study].

    by Qing-Hua Liu, Li-Xian He, Bi-Jie Hu, Jie-Ming Qu, Hua-Yin Li, Xue-Hua Chen, Xiao-Dong Gao, Jing Zhang

    To study the role of microorganisms in the gastro-intestinal (GI) tract in the development of ventilator-associated pneumonia (VAP). Forty-four healthy New Zealand white rabbits were randomly divided into a control group (n = 2), a mechanical ventilation (MV) group (n = 5), a mechanical ventilation with bacterial gastric inoculation (B) group (n = 11), a mechanical ventilation with bacterial gastric inoculation plus mosapride citrate (P) group (n = 13), and a mechanical ventilation with bacterial gastric inoculation plus loperamide (I) group (n = 13). 5% NaHCO3 was used to remain the pH value of gastric juices higher than 3.0. The flora in oropharynx, bronchi, and gastric juices were monitored during mechanical ventilation (MV). The pulmonary score and bacterial culture of the lung were performed at the end of mechanical ventilation. The incidence of lung infection caused by gastric bacterial inoculation was 10.8% (4/37). Taken together, mosapride citrate and loperamide didn't alter the incidence of VAP (chi2 = 0.83, P > 0.05), however, the occurrence of lung infection caused by inoculated bacteria in P group was lower than that in I group [(0.0%, 0/13) vs (23.1%, 3/13), chi2 = 4.55, P < 0.05]; the time of the emergence of the gastric inoculated bacteria in oropharynx in P group was later than that in I group; and the pulmonary score of B group was higher than that of MV group. Bacteria in the GI tract were not the main source of early-onset VAP, however, they may contribute to the development of late-onset VAP. Gastrointestinal dynamic promoting drugs, which enhance gastrointestinal motility, are useful to reduce the incidence of VAP caused by bacteria colonized in the digestive tract.